Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr80 Inhibitors

Olr80 inhibitors represent a fascinating class of chemical compounds that primarily function by targeting the Olr80 receptor, a specific type of olfactory receptor. Olfactory receptors, which are G-protein coupled receptors (GPCRs), are primarily known for their role in the detection of odor molecules, contributing to the sense of smell. However, recent research has uncovered that these receptors are also present in various non-olfactory tissues, indicating a broader range of biological roles. Olr80 inhibitors are designed to selectively bind to and modulate the activity of the Olr80 receptor, thereby influencing the signaling pathways and physiological processes associated with this receptor. The development of these inhibitors involves intricate chemical synthesis and optimization processes to achieve high specificity and potency.

The structure-activity relationship (SAR) studies of Olr80 inhibitors are critical for understanding their binding mechanisms and enhancing their efficacy. These inhibitors often feature diverse chemical scaffolds, including heterocyclic compounds, which are modified to improve receptor binding and selectivity. The binding interactions between Olr80 inhibitors and the receptor are characterized by a combination of hydrogen bonding, hydrophobic interactions, and Van der Waals forces. Advanced techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed to elucidate the precise binding conformations and molecular dynamics. Additionally, computational modeling and molecular docking studies play a significant role in predicting the interaction profiles and optimizing the inhibitor design. The study of Olr80 inhibitors not only advances our understanding of olfactory receptor function beyond traditional sensory perception but also opens new avenues in chemical biology and receptor pharmacology.

SEE ALSO...

Items 11 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL inhibitor, could indirectly affect Olr80 through altered kinase signaling.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR inhibitor, might modulate EGFR signaling pathways related to Olr80.